Tuesday, October 10, 2017

Allergan: FDA Accepts NDA For Ulipristal Acetate For Uterine Fibroids

Allergan plc (AGN) said that the U.S. Food and Drug Administration has accepted the New Drug Application or NDA for ulipristal acetate, an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids.

from RTT - Biotech http://ift.tt/2i1yzbL
via IFTTT

No comments:

Post a Comment